Portfolio Updates: Nabriva Therapeutics (NBRV), Aimmune Therapeutics (AIMT), Versartis (VSAR), Scynexis (SCYX), Radius Health (RDUS), Acorda Therapeutics (ACOR)

NBRV, AIMT, VSAR

We want to draw investor attention to Nabriva Therapeutics (NBRV), another open position. The company will present data from an on-going phase 3 data of Lefamulin, a first-in-class pleuromotilin antibiotic in adult community acquired bacterial pneumonia (CABP) in Q3, 2017. The company was enrolle...

We want to draw investor attention to Nabriva Therapeutics (NBRV), another open position. The company will present data from an on-going phase 3 data of Lefamulin, a first-in-class pleuromotilin antibiotic in adult community acquired bacterial pneumonia (CABP) in Q3, 2017. The company was enrolle...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics